The global macular degeneration treatment market size is expected to grow from $7.55 billion in 2021 to $8.08 billion in 2022 at a compound annual growth rate (CAGR) of 7.04%. The growth in the market is mainly due to the companies' resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global macular degeneration treatment market size is expected to reach $10.65 billion in 2026 at a CAGR of 7.15%.
What is the Global Macular Degeneration Treatment Market?
The macular degeneration treatment market consists of sales of macular degeneration treatment by entities (organizations, sole traders, and partnerships) that are used to treat macular degeneration eye disease. Macula refers to the central portion of the retina, a light-sensitive layer of tissue at the backside of the eye. The macula is responsible for central vision. Degeneration of the macula, which affects the central part of the retina (the macula) and results in distortion or loss of central vision, occurs most commonly after the age of 60 and is referred to as age-related macular generation (AMD). Macular degeneration treatment helps to slow the disease and prevent severe loss of vision.
Get a Sample of the global macular degeneration treatment market report
https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp
What drives the Global Macular Degeneration Treatment Market?
The increasing burden of retinal disorders is expected to propel the growth of the macular degeneration treatment market. Retinal disorders affect the vital tissue and affect the way individuals process visual information, leading to distorted or absent vision. According to a study done in Tanzania in 2020 about the prevalence of retinal diseases and associated risk factors, out of 1,007 people, the prevalence of vitreoretinal disorders was 22.8% (230/1,007). The study was conducted by OSLI Retina, which focuses solely on retinal diseases, surgery, and pharmacotherapy. The leading retinal diseases were age-related hypertensive macular scars (2.7%), retinopathy (4.5%), and degeneration (7.0%). According to the American Academy of Ophthalmology, in 2050, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, with the highest numbers among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Therefore, the increasing burden of retinal disorders is driving the growth of the macular degeneration treatment market.
Get the full global macular degeneration treatment industry report here
https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report
Global Macular Degeneration Treatment Market Segments
The global macular degeneration treatment market is segmented:
By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD
By End-User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals
By Route of Administration: Oral, Injectable, Others
By Type: Wet Macular Degeneration, Dry Macular Degeneration
By Geography: The regions covered in the macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Macular Degeneration Treatment Global Market Report 2022provides market size and growth forecasts for the global macular degeneration treatment market, global macular degeneration treatment market share, macular degeneration treatment market segments and geographies, macular degeneration treatment market competitive landscape including leading competitors’ revenues, profiles and market shares. The macular degeneration treatment market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Global Macular Degeneration Treatment Industry Playersinclude Novartis AG, Bausch Health Companies Inc, Regenxbio Inc, F Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, GlaxoSmithKline plc, Bayer AG, Neurotech Pharmaceuticals Inc, Ophthotech Corporation, StemCells Inc, Pfizer Inc, Santen Pharmaceuticals, Alimera Sciences Inc, Aerie Pharmaceutical Inc, Panoptica, Allergan Inc, Valeant Pharmaceuticals, and Rxi Pharmaceuticals. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.
